The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
Company Details
- Employees
- 4
- Address
- Cumberland, Md 21502, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- HQ
- Cumberland, MD
Rs Biotherapeutics, Inc. Questions
Rs Biotherapeutics, Inc.'s website is https://www.RSBioTherapeutics.com
Rs Biotherapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/rs-biotherapeutics
Rs Biotherapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Rs Biotherapeutics, Inc..
Rs Biotherapeutics, Inc.'s industry is
Pharmaceutical Manufacturing
Rs Biotherapeutics, Inc.'s top competitors are
Merit Cro,
Predictive Oncology,
Vivaldi Biosciences,
Rs Therapeutics Inc.,
Glyscend Therapeutics,
Novus Physical Medicine & Pain Management,
Gid Bio, Inc.,
Salubris Biotherapeutics,
Aytu Biopharma,
Pantheon Vision.
Rs Biotherapeutics, Inc.'s categories are Pharmaceutical Manufacturing
